Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Classical Hodgkin Lymphoma
Conditions
Classical Hodgkin Lymphoma
Trial Timeline
Oct 7, 2021 → May 26, 2024
NCT ID
NCT05008224About Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone is a phase 2 stage product being developed by Merck for Classical Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05008224. Target conditions include Classical Hodgkin Lymphoma.
What happened to similar drugs?
0 of 2 similar drugs in Classical Hodgkin Lymphoma were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05008224 | Phase 2 | Completed |
Competing Products
11 competing products in Classical Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Camrelizumab + Investigator's choice of Chemotherapy | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| Sabestomig (AZD7789) | AstraZeneca | Phase 1 | 29 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin | Merck | Phase 2 | 42 |
| Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate | Merck | Phase 2 | 31 |
| Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Merck | Phase 2 | 31 |
| Pembrolizumab (+) Berahyaluronidase alfa | Merck | Phase 2 | 39 |
| Panobinostat | Novartis | Phase 2 | 35 |
| PD1 | Innovent Biologics | Phase 2 | 35 |
| Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine | Bristol Myers Squibb | Phase 1 | 33 |
| Tislelizumab + Salvage Chemotherapy | BeOne Medicines | Phase 3 | 29 |
| GEN3017 | Genmab | Phase 1/2 | 21 |